Fig. 3From: Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancerRelative change from baseline in target lesion size (at the best tumor response). Shown is the percent change in the lowest sum of the target lesions from the baseline for patients who were on treatment for 3 cycles. Twenty-three patients had documented RAS and Braf genetic alterationsBack to article page